Corporate ActionJul 24, 2026, 04:32 PM
China SXT Pharmaceuticals Closes $9M Registered Direct Offering
AI Summary
China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering on July 24, 2026, generating approximately $9 million in gross proceeds. The company issued 4,500,000 units, each comprising one Class A ordinary share and one common warrant, at a purchase price of $2.00 per unit. Univest Securities, LLC served as the placement agent, receiving a 7.0% cash fee and up to $50,000 for expenses.
Key Highlights
- Closed a registered direct offering, raising approximately $9 million in gross proceeds.
- Issued 4,500,000 units, each priced at $2.00.
- Each unit consists of one Class A ordinary share and one common warrant.
- Warrants are immediately exercisable with an exercise price of $3.20 per share.
- Warrants will expire on the one-year anniversary of their issuance.
- Paid Univest Securities, LLC a 7.0% cash fee for acting as placement agent.
- Reimbursed placement agent up to $50,000 for non-accountable expenses.
Price Impact
More from SXTC